NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary.
“We are pleased to welcome Barbara to our executive team. Barbara has extensive experience both as a biotech executive and a corporate lawyer, along with valuable expertise in licensing, acquisitions, divestitures, collaborations, intellectual property, and strategic corporate development as well as commercial matters, which will undoubtedly support the continued growth and success of SELLAS,” said President and CEO, Angelos Stergiou, M.D., ScD h.c. “As we continue our maturation into a late-stage development company and advance galinpepimut-S (GPS), our lead product candidate, to Phase 3 clinical trials, Barbara’s leadership and executive and legal experience will be of immense value.”
“I am excited to join SELLAS’ dynamic leadership team and look forward to contributing to the Company’s growth at this critical time,” said Ms. Wood. “I am eager to work with the SELLAS team to realize the potential of SELLAS’ promising pipeline.”
Ms. Wood joins SELLAS having most recently served as Senior Vice President, General Counsel and Secretary for Ophthotech Corporation, where she supported corporate growth by advising on commercial and collaborative agreements and transactions, securities laws compliance and key strategic and legal issues. Before joining Ophthotech in 2013, she served as Senior Vice President and General Counsel at OSI Pharmaceuticals, where she built the company’s legal department and served as a key member of the senior management team through the company’s acquisition by Astellas Pharma in 2010. Earlier in her career, she was a Partner at Squadron Ellenoff, where she focused on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters.
Ms. Wood holds a B.A. in Classics and Economics from Connecticut College and a J.D. from Columbia University School of Law.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Stern Investor Relations, Inc.
David Moser, JD
SELLAS Life Sciences Group, Inc.
Source:SELLAS Life Sciences Group